We have located links that may give you full text access.
Journal Article
Randomized Controlled Trial
A pilot randomized study on use of oral acetazolamide in patients with refractory dysuria.
International Urology and Nephrology 2017 June
PURPOSE: Assessment of daily oral acetazolamide in treatment of refractory dysuria.
METHODS: Forty-one patients were randomly allocated to either be treated with acetazolamide (250 mg twice daily) or to receive placebo. The irritative voiding symptoms and urinary pH were recorded before and after treatment. The quality of life indices including the impact of voiding symptoms on daily and social activities, mood disturbance and sleep disorders were also measured by a questionnaire.
RESULTS: Urinary pH was increased in the group taking acetazolamide (P < 0.001). They also reported alleviation of dysuria (P < 0.001), frequency (P = 0.039) and urgency (P = 0.016). However, nocturia was not improved in the study group. No change was observed in the aforementioned parameters in the placebo group. Daily personal life, social activities and the quality of sleep were improved by 52, 38 and 33%, respectively.
CONCLUSION: Oral acetazolamide can reduce the irritative voiding symptoms and improve the quality of life which is concomitant with an increase in urinary pH.
METHODS: Forty-one patients were randomly allocated to either be treated with acetazolamide (250 mg twice daily) or to receive placebo. The irritative voiding symptoms and urinary pH were recorded before and after treatment. The quality of life indices including the impact of voiding symptoms on daily and social activities, mood disturbance and sleep disorders were also measured by a questionnaire.
RESULTS: Urinary pH was increased in the group taking acetazolamide (P < 0.001). They also reported alleviation of dysuria (P < 0.001), frequency (P = 0.039) and urgency (P = 0.016). However, nocturia was not improved in the study group. No change was observed in the aforementioned parameters in the placebo group. Daily personal life, social activities and the quality of sleep were improved by 52, 38 and 33%, respectively.
CONCLUSION: Oral acetazolamide can reduce the irritative voiding symptoms and improve the quality of life which is concomitant with an increase in urinary pH.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app